2023
Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer.
Zaidi S, Chan J, Love J, Zhao J, Setty M, Lawrence K, Gopalan A, Goodrich D, Morris M, Chen Y, Karthaus W, Pe'er D, Sawyers C. Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer. Journal Of Clinical Oncology 2023, 41: 227-227. DOI: 10.1200/jco.2023.41.6_suppl.227.Peer-Reviewed Original ResearchAndrogen receptor signaling inhibitorsFDA-approved inhibitorFibroblast growth factor receptorLineage plasticityProstate cancerAndrogen receptorInhibitors of JAK/STATSuccess of targeted cancer therapyCastration resistant prostate cancerSignaling inhibitorsLoss of tumor suppressor genesCases of prostate cancerFibroblast growth factor receptor signaling pathwayJanus kinaseSingle cell RNA analysisRadiologically guided biopsyResistant prostate cancerEffects of Janus kinaseIncreased androgen receptorTumor-derived organoidsGenetic editing toolsResistance to therapySingle cell RNA sequencingGrowth factor receptorTumor suppressor gene
2022
Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation.
Barnett E, Carbone E, Keegan N, Vasselman S, Nweji B, Zaidi S, Scher H. Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation. Journal Of Clinical Oncology 2022, 40: 5029-5029. DOI: 10.1200/jco.2022.40.16_suppl.5029.Peer-Reviewed Original ResearchCastration resistant prostate cancerCastrate resistant prostate cancer samplesNeuroendocrine prostate cancerHistological transformationRB1 alterationsProstate cancerDevelopment of neuroendocrine prostate cancerInhibits androgen receptor signalingNeuroendocrine prostate cancer patientsConfidence intervalsEvidence of neuroendocrine differentiationResistant prostate cancerProstate cancer patientsAndrogen receptor signalingIRB-approved protocolFOXA1 mutationsSequencing resultsTP53 alterationsAR alterationsNeuroendocrine differentiationMSK-IMPACTDifferentially altered genesPathology reportsPanel sequencingDisease course
2021
Prostate cancer research in the 21st century; report from the 2021 Coffey‐Holden prostate cancer academy meeting
Miyahira A, Zarif J, Coombs C, Flavell R, Russo J, Zaidi S, Zhao D, Zhao S, Pienta K, Soule H. Prostate cancer research in the 21st century; report from the 2021 Coffey‐Holden prostate cancer academy meeting. The Prostate 2021, 82: 169-181. PMID: 34734426, PMCID: PMC8688282, DOI: 10.1002/pros.24262.Peer-Reviewed Original ResearchConceptsCoffey-Holden Prostate Cancer Academy MeetingCoffey-Holden Prostate Cancer AcademyProstate cancer researchProstate cancerMetastatic castration resistant prostate cancerCastration resistant prostate cancerResistant prostate cancerProstate cancer biologyProstate Cancer FoundationCancer researchAntitumor immunityCancer immunotherapyClonal hematopoiesisMediators of plasticityTumor microenvironmentTargeted therapyProstateCell plasticityCancer FoundationCancer biologyCancerSignaling pathwayCancer genomesSignaling biologyAcademy Meeting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply